Phase-3 trial of recombinant human alkaline phosphatase for patients with sepsis-associated acute kidney injury (REVIVAL)

Purpose Ilofotase alfa is a human recombinant alkaline phosphatase with reno-protective effects that showed improved survival and reduced Major Adverse Kidney Events by 90 days (MAKE90) in sepsis-associated acute kidney injury (SA-AKI) patients. REVIVAL, was a phase-3 trial conducted to confirm its...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Intensive care medicine 2024, Vol.50 (1), p.68-78
Hauptverfasser:	Pickkers, Peter, Angus, Derek C., Bass, Kristie, Bellomo, Rinaldo, van den Berg, Erik, Bernholz, Juliane, Bestle, Morten H., Doi, Kent, Doig, Chistopher J., Ferrer, Ricard, Francois, Bruno, Gammelager, Henrik, Pedersen, Ulf Goettrup, Hoste, Eric, Iversen, Susanne, Joannidis, Michael, Kellum, John A., Liu, Kathleen, Meersch, Melanie, Mehta, Ravindra, Millington, Scott, Murray, Patrick T., Nichol, Alistair, Ostermann, Marlies, Pettilä, Ville, Solling, Christoffer, Winkel, Matthias, Young, Paul J., Zarbock, Alexander
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute Kidney Injury - drug therapy Acute Kidney Injury - etiology Alkaline phosphatase Alkaline Phosphatase - therapeutic use Analysis Anesthesiology Care and treatment Critical Care Medicine Effectiveness Emergency Medicine Health aspects Health care industry Humans Infection Intensive Intensive care Intensive Care Units Kidneys Medical equipment and supplies industry Medical test kit industry Medicine Medicine & Public Health Mortality NCT NCT04411472 Original Pain Medicine Pediatrics Pharmaceutical industry Phosphatase Phosphatases Placebos Pneumology/Respiratory System Product development Safety Sepsis Sepsis - complications Sepsis - drug therapy Statistical analysis Survival
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!